98% OVERALL
RESPONSE RATE
(95/97 95% CI: 92.7-99.7)a
78% STRINGENT
COMPLETE RESPONSE
(76/97 95% CI: 68.8-86.1)ab
17% VERY GOOD
PARTIAL RESPONSE
(16/97 95% CI: 9.7-25.4)a
3% PARTIAL
RESPONSE
(3/97 95% CI: 0.6-8.8)a

Learn more about deep responses

21.8 MONTHS MEDIAN DURATION
OF RESPONSE
(95% CI: 21.8-NE)a

Learn more about durable responses

CARVYKTI™ is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

How it works

Learn how CARVYKTI™ targets BCMA

Study Design

Learn about the CARTITUDE-1 Study Design

Chart

Review the CARTITUDE-1 safety profile

Resources Icon

Find educational resources to support your patients

CARTITUDE-1 was a Phase 1b/2 open-label, multicenter study evaluating the efficacy and safety of a single infusion of ciltacabtagene autoleucel in adult patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In total, 97 patients were treated with ciltacabtagene autoleucel; all were evaluable for efficacy. Primary endpoint in Phase 1b was safety. Primary efficacy endpoint in Phase 2 was overall response rate; selected secondary endpoints included stringent complete response, very good partial response, minimal residual disease negativity, duration of response, progression-free survival, and safety.1,2

CD38=cluster of differentiation 38; CI=confidence interval; NE=not estimable.

aBased on a median duration of follow-up of 18 months.

bAll complete responses were stringent complete responses.

Learn more about CARVYKTI
Register to be contacted by a representative